Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study
{{output}}
Background: Despite advances in risk-adapted chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT), relapse remains the leading cause of treatment failure and mortality in pediatric acute lymphoblastic l... ...
